Advertisement

Tumor Biology

, Volume 35, Issue 7, pp 6283–6291 | Cite as

Immunohistochemical expression pattern of MMR protein can specifically identify patients with colorectal cancer microsatellite instability

  • Arfaoui Toumi Amira
  • Trabelsi Mouna
  • Blel Ahlem
  • Aloui Raoudha
  • Ben Hmida Majid
  • Hamza Amel
  • Zermani Rachida
  • Kourdaa Nadia
Research Article

Abstract

The microsatellite instability (MSI) pathway is found in most cases of hereditary nonpolyposis colorectal cancer (HNPCC) and in 12 % of sporadic colorectal cancer (CRC). It involves inactivation of deoxyribonucleic acid mismatch repair (MMR) genes MLH1, MSH2, PMS2, and MSH6. MMR germline mutation detections are an important supplement to HNPCC clinical diagnosis. It enables at-risk and mutation-positive relatives to be informed about their cancer risks and to benefit from intensive surveillance programs that have been proven to reduce the incidence of CRC. In this study, we analyzed for the first time in Tunisia the potential value of immunohistochemical assessment of MMR protein to identify microsatellite instability in CRC. We evaluate by immunohistochemistry MMR protein expression loss in tumoral tissue compared to positive expression in normal mucosa. Immunohistochemistry revealed loss of expression for MLH1, MSH2, MSH6, and PMS2 in 15, 21, 13, and 15 % of cases, respectively. Here, we report a more elevated frequency of MSI compared to data of the literature. In fact, by immunohistochemistry, 70 % of cases were shown to be MSS phenotype, whereas 30 % of cases, in our set, were instable. Moreover, according to molecular investigation, 71 % of cases were instable (MSI-H) and remaining cases were stable (29 %). Thus, we found a perfect association between MMR immunohistochemical analyses and MSI molecular investigation. Immunohistochemical analysis of MMR gene product expression may allow one to specifically identify MSI phenotype of patients with colorectal carcinomas.

Keywords

Colorectal carcinomas Immunohistochemistry MSI phenotype MSI status MMR genes Microsatellite instability 

Notes

Acknowledgements

This study was supported by a grant from the Ministry of Higher Education and Scientific Research of Tunisia. We thank Dr. Marie Pierre Buisine who performed all the molecular analyses in the Laboratory of Biochemistry and Molecular Biology HMNO, Department of Oncology and Molecular Genetics, University Hospital of Lille, 59000 Lille, France.

Conflicts of interest

None

References

  1. 1.
    Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Rüschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 1997;57:4749–56.PubMedGoogle Scholar
  2. 2.
    Wheeler JMD. Epigenetics, mismatch repair genes and colorectal cancer. Ann R Coll Surg Engl. 2005;87:15–20.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Kin C, Kidess E, Poultsides GA, Visser BC, Jeffrey SS. Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. Expert Rev Mol Diagn. 2013;6:581–99.CrossRefGoogle Scholar
  4. 4.
    Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63(1):11–30.CrossRefPubMedGoogle Scholar
  5. 5.
    O'Regan T, Chau K, Tatton M, Smith T, Parry S, Bissett I. Immunochemistry screening for Lynch syndrome in colorectal adenocarcinoma using an initial two antibody panel can replace a four antibody panel. N Z Med J. 2013;126:70–7.PubMedGoogle Scholar
  6. 6.
    Garre P, Martín L, Bando I, Tosar A, Llovet P, Sanz J, et al. Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer. Fam Cancer. 2013;13(1):109–19.CrossRefGoogle Scholar
  7. 7.
    Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond Lynch syndrome. Clin Gastroenterol Hepatol. 2013.Google Scholar
  8. 8.
    Kheirelseid EA, Miller N, Chang KH, Curran C, Hennessey E, Sheehan M, et al. Mismatch repair protein expression in colorectal cancer. J Gastrointest Oncol. 2013;4(4):397–408.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Win AK, Macinnis RJ, Dowty JG, Jenkins MA. Criteria and prediction models for mismatch repair gene mutations: a review. J Med Genet. 2013;50(12):785–93.CrossRefPubMedGoogle Scholar
  10. 10.
    Oliveira C, Seruca R, Seixas M, Sobrinho-Simoes M. The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different “target genes”: a study of the TGFbeta RII, IGFII R, and BAX genes. Am J Pathol. 1998;153:1211–9.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Boland GM, Chang GJ, Haynes AB, Chiang YJ, Chagpar R, Xing Y, et al. Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer. 2013;119(8):1593–601.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Hartman DJ, Brand RE, Hu H, Bahary N, Dudley B, Chiosea SI, et al. Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach. Hum Pathol. 2013;44(11):2518–28.CrossRefPubMedGoogle Scholar
  13. 13.
    Kloor M. Pathogenesis of microsatellite-unstable colorectal cancer. Evaluation of new diagnostic and therapeutic options. Pathologe. 2013;34 Suppl 2:277–81.CrossRefPubMedGoogle Scholar
  14. 14.
    Umar A, Risinger JI, Hawk ET, Barrett JC. Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer. 2004;4:153–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology. 2002;123:1804–11.CrossRefPubMedGoogle Scholar
  16. 16.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMedGoogle Scholar
  17. 17.
    Mostert B, Jiang Y, Sieuwerts AM, Wang H, Bolt-de Vries J, Biermann K, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer. 2013;133(1):130–41.CrossRefPubMedGoogle Scholar
  18. 18.
    De la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 2010;28(20):3380–7.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Michael-Robinson JM, Reid LE, Purdie DM, Biemer-Hüttmann AE, Walsh MD, Pandeya N, et al. Proliferation, apoptosis, and survival in high-level microsatellite instability sporadic colorectal cancer. Clin Cancer Res. 2001;7(8):2347–56.PubMedGoogle Scholar
  20. 20.
    Esemuede I, Forslund A, Khan SA, Qin LX, Gimbel MI, Nash GM, et al. Improved testing for microsatellite instability in colorectal cancer using a simplified 3-marker assay. Ann Surg Oncol. 2010;17(12):3370–8.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Edmonston TB, Cuesta KH, Burkholder S, Barusevicius A, Rose D, Kovatich AJ, et al. Colorectal carcinomas with high microsatellite instability: defining a distinct immunologic and molecular entity with respect to prognostic markers. Hum Pathol. 2000;31(12):1506–14.CrossRefPubMedGoogle Scholar
  22. 22.
    Niv Y. Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil. Isr Med Assoc J. 2005;7(8):520–4.PubMedGoogle Scholar
  23. 23.
    Hemminki A, Mecklin JP, Järvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology. 2000;119(4):921–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer. 2001;1(2):104–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, Goossens M, Ouchene H, Hendriks-Cornelissen SJ, et al.Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology. 2013 [Epub ahead of print].Google Scholar
  26. 26.
    Aissi S, Buisine MP, Zerimech F, Kourda N, Moussa A, Manai M, et al. Somatic molecular changes and histo-pathological features of colorectal cancer in Tunisia. World J Gastroenterol. 2013;19(32):5286–94.PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Marra G, Jiricny J. DNA mismatch repair and colon cancer. Adv Exp Med Biol. 2005;570:85–123.CrossRefPubMedGoogle Scholar
  28. 28.
    Rigau V, Nicole Sebbagh BS, Sylviane O, Francois P, Najat M, Yann P, et al. Microsatellite instability in colorectal carcinoma: the comparison of immunohistochemistry and molecular biology suggests a role for hMLH6 immunostaining. Arch Pathol Lab Med. 2003;127:694–700.PubMedGoogle Scholar
  29. 29.
    Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst. 2012;104(21):1635–46.CrossRefPubMedGoogle Scholar
  30. 30.
    Kang BW, Kim JG, Lee SJ, Chae YS, Moon JH, Sohn SK, et al. Clinical significance of microsatellite instability for stage II or III colorectal cancer following adjuvant therapy with doxifluridine. Med Oncol. 2011;28(1):214–8.CrossRefGoogle Scholar
  31. 31.
    Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997;57:808–11.PubMedGoogle Scholar
  32. 32.
    Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Mod Pathol. 2002;15(7):741–9.CrossRefGoogle Scholar
  33. 33.
    Kria Ben Mahmoud L, Arfaoui A, Khiari M, Chaar I, Lounis A, Sammoud S, et al. Evaluation of microsatellite instability, MLH1 expression and hMLH1 promoter hypermethylation in colorectal carcinomas among Tunisians patients. Tunis Med. 2012;90(8-9):646–53.PubMedGoogle Scholar
  34. 34.
    Malhotra P, Anwar M, Kochhar R, Ahmad S, Vaiphei K, Mahmood S. Promoter methylation and immunohistochemical expression of hMLH1 and hMSH2 in sporadic colorectal cancer: a study from India. Tumour Biol. 2013. doi: 10.1007/s13277-013-1487-3.
  35. 35.
    Lawes DA, Pearson T, SenGupta S, Boulos PB. The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers. Br J Cancer. 2005;93:472–7.PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Lech G, Slotwinski R, Krasnodebski IW. The role of tumor markers and biomarkers in colorectal cancer. Neoplasma. 2014;61(1):1–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Patil DT, Bronner MP, Portier BP, Fraser CR, Plesec TP, Liu X. A five-marker panel in a multiplex PCR accurately detects microsatellite instability-high colorectal tumors without control DNA. Diagn Mol Pathol. 2012;21(3):127–33.CrossRefPubMedGoogle Scholar
  38. 38.
    Serrano M, Lage P, Belga S, Filipe B, Francisco I, Rodrigues P, et al. Bethesda criteria for microsatellite instability testing: impact on the detection of new cases of Lynch syndrome. Fam Cancer. 2012;11(4):571–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Lanza G, Gafà R, Maestri I, Santini A, Matteuzzi M, Cavazzini L. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol. 2002;15(7):741–9.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Arfaoui Toumi Amira
    • 1
    • 3
  • Trabelsi Mouna
    • 1
  • Blel Ahlem
    • 1
  • Aloui Raoudha
    • 1
  • Ben Hmida Majid
    • 2
  • Hamza Amel
    • 1
  • Zermani Rachida
    • 1
  • Kourdaa Nadia
    • 1
  1. 1.Department of PathologyCharles Nicolle HospitalTunisTunisia
  2. 2.Department of Preventive MedicineMedical University of TunisiaTunisTunisia
  3. 3.la SoukraTunisia

Personalised recommendations